<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5017">
  <stage>Registered</stage>
  <submitdate>19/05/2014</submitdate>
  <approvaldate>19/05/2014</approvaldate>
  <nctid>NCT02143791</nctid>
  <trial_identification>
    <studytitle>Evaluate St Jude Medical Prodigy Neuromodulation for FBSS or Chronic Pain of the Trunk and/or Limbs</studytitle>
    <scientifictitle>A Post-market Study Evaluating the Prodigy Neuromodulation System for the Management of Failed Back Surgery Syndrome or Chronic Intractable Pain of the Trunk and/or Limbs.</scientifictitle>
    <utrn />
    <trialacronym>Prodigy-I</trialacronym>
    <secondaryid>NM-13-038-ID-SC</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - Burst stimulation
Treatment: devices - Prodigy system

Burst stimulation - At permanent implant with the Prodigy system, patients will be programmed with Burst stimulation


Treatment: surgery: Burst stimulation


Treatment: devices: Prodigy system


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint is the percentage of pain relief at the 3-month visit compared to baseline visit, as measured by the Visual Analog Scale (VAS).</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of serious adverse events (SAEs) and/or procedure/device-related adverse events ((S)ADEs)</outcome>
      <timepoint>from enrollment to 12 months follow up</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient with chronic, intractable pain of the trunk and/or limbs, including unilateral
             or bilateral pain associated with the following: failed back surgery syndrome or
             intractable low back and/or leg pain

          -  Patient is considered by the investigator as a candidate for implantation of a SCS
             system

          -  Patient is = 18 years of age

          -  Patient must be willing and able to comply with study requirements

          -  Patient must indicate his/her understanding of the study and willingness to
             participate by signing an appropriate Informed Consent Form</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patient is immune-compromised

          -  Patient has history of cancer requiring active treatment in the last 6 months

          -  Patient has a documented history of substance abuse (narcotics, alcohol, etc.) or
             substance dependency in the last 6 months

          -  Patients with a SCS system or implantable infusion pump implanted previously

          -  Patient has a life expectancy of less than one year

          -  Patient is pregnant or is planning to become pregnant during the duration of the
             investigation

          -  Patient is unable to comply with the follow up schedule

          -  Patient needing legally authorized representative

          -  Patient unable to read and write

          -  Patient is currently participating in another clinical investigation with an active
             treatment arm</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>126</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Metro Spinal Clinic - Caulfield</hospital>
    <hospital>Frankston Pain Management - Frankston</hospital>
    <hospital>Epworth Hospital - Richmond</hospital>
    <postcode>3162 - Caulfield</postcode>
    <postcode> - Frankston</postcode>
    <postcode> - Richmond</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Duesseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gera</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>KÃ¶ln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Magdeburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tubingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Enschede</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nieuwegein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Velp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesbrough</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to confirm long term efficacy and safety of the ProdigyTM
      neuromodulation system in the management of failed back surgery syndrome or chronic
      intractable pain of the trunk and/or limbs.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02143791</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tony Van Havenbergh</name>
      <address>St Augustinus, Wilrijk, Belgium</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>